Placulumab

Drug Profile

Placulumab

Alternative Names: Anti-TNF alpha antibody; Anti-tumour necrosis factor alpha antibody; ART-621; CEP-37247; PN-0621

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Domantis; Peptech
  • Developer Arana Therapeutics; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antibodies; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Psoriasis; Rheumatoid arthritis
  • Discontinued Sciatica

Most Recent Events

  • 30 Apr 2013 Cephalon completes a phase I/II trial in Sciatica in USA and Australia (NCT01240876)
  • 18 Jun 2012 Cephalon completes enrolment in its phase I/II trial for Sciatica in USA and Australia (NCT01240876)
  • 08 Mar 2011 No development reported - Phase-II for Psoriasis in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top